Decoding Secreted Proteins for Chronic and Rare Diseases
Location: United States, California, Redwood City
Total raised: $41M
Founded date: 2017
Investors 8
| Date | Name | Website |
| 25.11.2022 | Transform ... | transform.... |
| 20.06.2021 | Open Field... | ofcap.com |
| - | Harmonix | harmonixfu... |
| - | Longevityt... | longevityt... |
| 12.06.2021 | Creative D... | creativede... |
| 23.12.2020 | Felicis Ve... | felicis.co... |
| - | Refactor C... | refactor.c... |
| 06.04.2022 | Manta Ray ... | mantaray.v... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.11.2022 | Series A | $41M | - |
Mentions in press and media 9
| Date | Title | Description |
| 13.01.2026 | Juvena Therapeutics Raises $33.5M in Series B Funding | Juvena Therapeutics, a Redwood City, CA-based clinical-stage biotechnology company, raised $33.5M in Series B funding. The round was led by Bison Ventures with participation from Eli Lilly and Company, Jefferson Life Sciences, and existing ... |
| 17.08.2023 | The 30 young leaders who are forging a new future for the healthcare industry in 2023 | Your browser does not support the video element. This story is available exclusively to Insider subscribers. Become an Insider and start reading now. A new generation of leaders is transforming the healthcare industry. They're developing ne... |
| 09.02.2023 | Slone Partners Places Gayathri Swaminath as SVP of Discovery and Edward Moler as VP of Data Science at Juvena Therapeutics | “Gayathri Swaminath and Eddie Moler are both highly accomplished and respected thinkers and leaders in drug discovery and development and data science with a truly impressive depth of knowledge,” said Slone Partners President Tara Kochis. S... |
| 27.01.2023 | Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business Development | Neil Berkley, MBA, joins as Chief Corporate Development Officer Gayathri Swaminath, PhD, MBA, joins as Senior Vice President of Discovery Mo Tabrizi, PhD, joins as Vice President of Preclinical and Nonclinical Development Eddie Moler, PhD, ... |
| 08.11.2022 | Juvena Therapeutics Grabs $41M Series A | REDWOOD CITY, CA, Juvena Therapeutics announced today that it has raised $41 million in an oversubscribed Series A round. >> Click here for more funding data on Juvena Therapeutics >> To export Juvena Therapeutics funding da... |
| 08.11.2022 | Biotech Startup Juvena Therapeutics Nabs $41 Million for Protein Drugs | Biotechnology startup Juvena Therapeutics Inc. has raised $41 million in new venture-capital funding to advance technology that could expand the range of treatments for chronic conditions and diseases of aging. Redwood City, Calif.-based Ju... |
| 08.11.2022 | Juvena Therapeutics Raises $41M in Series A Funding | Juvena Therapeutics, a Redwood City, CA-based biotechnology company, raised $41M in Series A funding. The round was led by Mubadala Capital and Horizons Ventures, with participation from Bison Ventures, Manta Ray Ventures, IRONGREY, Alumni ... |
| - | Juvena Therapeutics | “Unlocking the therapeutic potential of secreted proteins Restoring tissue health and rejuvenating lives Learn about our impact Protein signaling dysregulation leads to degenerative diseases Juvena maps the therapeutic potential of natural ... |
| - | Juvena Therapeutics | “Juvena’s Protein Drug Discovery Engine Juvena Therapeutics is building a computationally driven protein drug discovery and development platform to decode the therapeutic potential of secreted proteins. Through Juvena’s extensive, multimoda... |